Trinity Delta research note & consensus forecasts
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces the publication of an analyst report by Trinity Delta which is available on the Company's website: https://www.futuramedical.com/investor-centre/shareholder-centre/analyst-research/
Following the release of the updated research, the company confirms that the equity analyst consensus market expectations for revenue for the year ending 31 December 2024 and 31 December 2025 are £13.4 million and £18.6 million respectively.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.